Navigation Links
Anticlotting drug found to be safe in sickle cell patients
Date:10/11/2007

CHAPEL HILL - An intravenous blood thinner widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found.

We have tested a potentially promising drug in sickle cell patients, and the drug appears to be well tolerated. This gives us the impetus to go ahead with further studies of eptifibatide in these patients, said Dr. Leslie V. Parise, department chair and professor of biochemistry and biophysics at the UNC-Chapel Hill School of Medicine.

The hallmark of sickle cell disease is malformed red blood cells that can cause sudden painful episodes when they block small blood vessels. However, sickle cell patients are also at increased risk of developing multiple other complications, including strokes, lung complications and pulmonary hypertension.

The most frequent manifestations of sickle cell disorders are anemia and pain episodes. The episodic exacerbation of pain, often called crises, is unpredictable and may occur often in some patients.

The only drug presently approved for the treatment of sickle cell disease is hydroxyurea, which has been shown to reduce the frequency of painful episodes.

Parise emphasized the need for further study. We did not test this drug in patients who are in crisis, and we cannot recommend that doctors prescribe this drug for sickle cell patients at this time, she said.

The results of the study were published online (Oct. 6) in the British Journal of Haematology.

The researchers gave intravenous infusions of eptifibatide (brand name Integrilin) to four patients with sickle cell anemia who were not experiencing pain episodes. They did well clinically. They did not experience any deleterious changes in their blood tests or have a pain episode, said coauthor Dr. Kenneth I. Ataga, assistant professor of medicine at UNC-Chapel Hill.

In the current study, blood tests showed that while the patients liver, kidney and other functions remained at baseline, several indicators of inflammation decreased, including levels of a protein called CD40L known to play a role in inflammation and in blood clotting.

Previous studies conducted by Sheritha Lee a graduate student in Parises lab showed that patients with sickle cell disease have CD40L levels that are as much as 30 times higher than in patients without the disease. Eptifibatides known ability to decrease CD40L led the researchers to study whether the drug might help sickle cell patients.


'/>"/>

Contact: Les Lang
LLANG@MED.UNC.EDU
919-843-9687
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. Distraction therapy found very effective in postoperative patients
2. Genetic differences found between Male and Female brains
3. Breastfeeding not found to have an impact on weight of the child.
4. Common Cold Found to Fight Cancer Cells
5. Mentally Demanding Jobs Found To Reduce The Risk Of Alzheimer’
6. Caffeine Found To Worsen Diabetes
7. Drug Found To Bring Relief For Individuals With Early Parkinson’
8. Environmental Factors Found To Have An Impact On The Sex of A Child
9. New molecule to treat brain disorders found
10. Higher Rates Of Diabetes Found Among The Poor
11. Antioxidants found in chocolates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology: